FDA Orange Book
Is there a generic for Trelstar?
Trelstar contains triptorelin. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Trelstar (triptorelin). The Orange Book shows its last listed patent expires June 30, 2029.
Run it in Rivvi
Map Trelstar and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Trelstar products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| injectable, intramuscular | EQ 11.25MG BASE/VIAL | Marketed (Rx) | None | 0 | None |
| injectable, intramuscular | EQ 22.5MG BASE/VIAL | Marketed (Rx) | None | 0 | None |
| injectable, intramuscular | EQ 3.75MG BASE/VIAL | Marketed (Rx) | None | 0 | None |
NDA 021288, 022437, 020715, held by VERITY PHARMACEUTICALS INC. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Trelstar patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 10166181 | June 30, 2029 | Drug product | None | 022437 |
Questions
Is there a generic for Trelstar?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Trelstar (triptorelin). The Orange Book shows its last listed patent expires June 30, 2029.
What is the generic name for Trelstar?
The active ingredient in Trelstar is triptorelin, per the FDA Orange Book.
When does the Trelstar patent expire?
The last patent listed for Trelstar in the Orange Book expires June 30, 2029. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.